Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 16/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057875 | 0.84 | FOLH1 (0.62) | FOLH1 | |
| SCHEMBL5054711 | 0.84 | FOLH1 (0.62) | FOLH1 | |
| SCHEMBL5057835 | 0.81 | FOLH1 (0.62) | FOLH1 | |
| SCHEMBL5053046 | 0.81 | FOLH1 (0.58) | FOLH1TSHRHTT | |
| SCHEMBL5051281 | 0.80 | FOLH1 (0.69) | FOLH1 | |
| SCHEMBL5057982 | 0.80 | FOLH1 (0.56) | FOLH1TSHR | |
| SCHEMBL5054201 | 0.78 | FOLH1 (0.44) | FOLH1TSHRHTT | |
| SCHEMBL5054206 | 0.77 | FOLH1 (0.46) | FOLH1TSHRHTT | |
| SCHEMBL5051284 | 0.77 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL5057797 | 0.76 | FOLH1 (0.62) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002057222-A9 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-11-20 | — | — | US | claimed |
| EP-1353903-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-10-22 | — | — | EP | claimed |
| US-6586623-B2 | Carbocyclic mercaptans such as 3-carboxy-alpha-(3-mercapto-propyl) benzenepropanoic acid, used as N-acetylated alpha-linked acidic dipeptidase(NAALADase) inhibitors and for medical diadnosis | GUILFORD PHARMACEUTICALS INC. | 2003-07-01 | — | — | US | claimed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060135812-A1 | Thiol-based NAALADase inhibitors | TSUKAMOTO TAKASHI | 2006-06-22 | — | — | US | disclosed |
| US-6992215-B2 | Thiol-based NAALADase inhibitors | GUILDFORD PHARMACEUTICALS INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | disclosed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | disclosed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | disclosed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135812-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, GGCT | FOLH1 7/4885TSHR 3763/4885HTT 1613/4885 |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | FOLH1 432/4885TSHR 4825/4885HTT 118/4885 |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885TSHR 3830/4885HTT 1514/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885TSHR 4275/4885HTT 4569/4885 |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885TSHR 3830/4885HTT 1514/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | FOLH1 124/4885TSHR 3404/4885HTT 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.